Perseus Proteomics (4882) · RiskRestated
Risk of serious adverse reactions involving investigational and marketed drugs
First written in FY2022. 2 of 3 entries say "Restated". Latest entry: FY2025.
3entries
4years
0from disclosures
How it moved
Same theme, other companies
Health Damage and Product Liability Risks Associated with PharmaceuticalsA theme 58 companies write about · 67 as a headwind · 1 as a tailwind
The whole theme swung hardest in 2026: 6 of 20 companies on the "Worse" side.
36 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 58 companies compared. The sentences above are computed from all 58.Full recordFilings, disclosures and news, newest first
- FY2025RestatedAnnual report
「Unexpected serious adverse reactions may occur with investigational drugs developed by the company and marketed drugs, from the clinical trial stage through after product launch.」
The risks of serious adverse reactions to investigational and marketed drugs, as well as product liability and damages, have been reconfirmed. - FY2023RestatedAnnual report
「Unexpected serious adverse reactions may occur with investigational drugs developed by the company and marketed drugs, from the clinical trial stage through after product launch.」
The risks of serious adverse reactions to investigational and marketed drugs, as well as product liability and damages, have been reconfirmed. - FY2022First statedAnnual report
「Unexpected serious adverse reactions may occur with investigational drugs developed by the company and marketed drugs, from the clinical trial stage through after product launch.」
The company identifies the occurrence of serious adverse reactions, product liability and damages, and the possibility that insurance may not fully cover losses as risks in pharmaceutical development.